Search Results for 'product biosimilar'
product biosimilar published presentations and documents on DocSlides.
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilar Biological Products
by luanne-stotts
2016 . Clinical Investigator . Training Course. S...
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
Biosimilars in the united states – Update on FDA Impleme
by test
James C. Shehan. Hyman, Phelps & McNamara, P....
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives
by alida-meadow
Richard Montes, Ph.D.. Hospira. , a Pfizer compan...
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Phil Johnson MS RPh Safe School Meds, Principle Partner
by yoshiko-marsland
Moffitt Cancer Center, Director of Pharmacy (Reti...
22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum
by carla
Adoption by CHMP for release for consultation24 Ma...
JMP for Biosimilars : Tools for Analytical Similarity
by erica
Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...
US Regulatory Pathway For Biosimilars
by cheryl-pisano
Practical Legal/Regulatory Considerations Arising...
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
by anastasia
x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Category 1: Defining Terms Clue: A biologic
by myesha-ticknor
Category 1: Defining Terms Clue: A biologic produc...
Biosimilars Knowledge Connect Slide Resource This
by ellena-manuel
Biosimilars Knowledge Connect Slide Resource This ...
Specialty Pharmacy and Biosimilars Created by the
by lois-ondreau
Specialty Pharmacy and Biosimilars Created by the ...
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
Latin American Physician Perspectives on Biosimilars
by celsa-spraggs
Presented at the . Latin American Biologics/Biosi...
ASBM Biosimilars US Prescribers and Biosimilars Naming
by min-jolicoeur
Kevin Olson, CEO. Industry Standard Research. Kev...
Biosimilars & EU regulation
by karlyn-bohler
Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...
Biosimilars 2012 AIPLA Webinar
by stefany-barnette
September 25, 2012. 1. Denise. Kettelberger, PhD...